{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:33:05Z","timestamp":1785000785798,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Sigmund Freud Privatuniversit\u00e4t Wien"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>Big data from large international cooperations allow proving consistency of findings in national patient cohorts. We compared features in <jats:italic>NRAS<\/jats:italic>-mutated patients of the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with the chronic myelomonocytic leukemia (CMML) cohort documented in cBioPortal. It is consistently demonstrated in both CMML cohorts that <jats:italic>NRAS<\/jats:italic> mutations are associated with shorter overall survival, acute myeloid leukemia-free survival, increased white blood cell count, decreased platelet values and the presence of blast cells in peripheral blood. Hemoglobin values did not differ between patients with or without <jats:italic>NRAS<\/jats:italic> mutations in either cohort. Validation of data in CMML patients using two independent cohorts, ensures the quality standards for clinical decision making.<\/jats:p>","DOI":"10.1007\/s10354-025-01080-0","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:42:45Z","timestamp":1747287765000},"page":"267-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics of NRAS-mutated patients with chronic myelomonocytic leukemia in a\u00a0national (ABCMML) and an international cohort (cBioPortal)","Charakteristika von Patienten mit NRAS-Mutation und chronischer myelomonozyt\u00e4rer Leuk\u00e4mie in einer nationalen (ABCMML) und einer internationalen Kohorte (cBioPortal)"],"prefix":"10.1007","volume":"175","author":[{"given":"Alexandra","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"2","key":"1080_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett\u00a0JM, Catovsky\u00a0D, Daniel\u00a0MT, et\u00a0al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"7","key":"1080_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman\u00a0JW, Harris\u00a0NL, Brunning\u00a0RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"issue":"5","key":"1080_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman\u00a0JW, Thiele\u00a0J, Arber\u00a0DA, et\u00a0al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"1080_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"1080_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0RP, et\u00a0al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"7","key":"1080_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury\u00a0JD, Solary\u00a0E, Abla\u00a0O, et\u00a0al. The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"1","key":"1080_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","volume":"95","author":"MM Patnaik","year":"2020","unstructured":"Patnaik\u00a0MM, Tefferi\u00a0A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97\u2013115.","journal-title":"Am J Hematol"},{"issue":"3","key":"1080_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida\u00a0F, Kantarjian\u00a0HM, Smith\u00a0TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213 patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"14","key":"1080_CR9","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska\u00a0AM, Makishima\u00a0H, Tiu\u00a0RV, et\u00a0al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932\u201341.","journal-title":"Blood"},{"issue":"24","key":"1080_CR10","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","volume":"28","author":"A Kohlmann","year":"2010","unstructured":"Kohlmann\u00a0A, Grossmann\u00a0V, Klein\u00a0HU, et\u00a0al. Next-generation sequencing technology reveals a\u00a0characteristic pattern of molecular mutations in 72.8\u202f% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J\u00a0Clin Oncol. 2010;28(24):3858\u201365.","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"1080_CR11","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Kosmider\u00a0O, Renneville\u00a0A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1080_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena\u00a0C, Gall\u00ec\u00a0A, Such\u00a0E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"1","key":"1080_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie\u00a0Y, Shao\u00a0L, Zhang\u00a0H, He\u00a0CK, Li\u00a0H, Zou\u00a0J, et\u00a0al. Mutational landscape of chronic myelomonocytic leukemia in chinese patients. Exp Hematol Oncol. 2022;11(1):32.","journal-title":"Exp Hematol Oncol"},{"issue":"17\u201318","key":"1080_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et\u00a0al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a\u00a0representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17\u201318):410\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"1080_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2288-13-33","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston\u00a0P, Altman\u00a0DG. External validation of a\u00a0cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13(1):33.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"1080_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami\u00a0E, Gao\u00a0J, Dogrusoz\u00a0U, et\u00a0al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"1080_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-025-01072-0","author":"M Grass","year":"2025","unstructured":"Grass M, Geissler K. Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL). Wien Med Wochenschr. 2025. https:\/\/doi.org\/10.1007\/s10354-025-01072-0.","journal-title":"Wien Med Wochenschr"},{"issue":"7","key":"1080_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard\u00a0E, Tuechler\u00a0H, Greenberg\u00a0PL, et\u00a0al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Nejm Evid. 2022;1(7):28. https:\/\/doi.org\/10.1056\/EVIDoa2200008.","journal-title":"Nejm Evid"},{"issue":"7","key":"1080_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","volume":"27","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Solary\u00a0E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441\u201350.","journal-title":"Leukemia"},{"issue":"8","key":"1080_CR20","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","volume":"15;16","author":"C Ricci","year":"2010","unstructured":"Ricci\u00a0C, Fermo\u00a0E, Corti\u00a0S, et\u00a0al. RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant. Clin Cancer Res. 2010;15;16(8):2246\u201356.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1080_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.23702","volume":"89","author":"N Cervera","year":"2014","unstructured":"Cervera\u00a0N, Itzykson\u00a0R, Coppin\u00a0E, et\u00a0al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. Am J Hematol. 2014;89(6):604\u20139.","journal-title":"Am J Hematol"},{"issue":"12","key":"1080_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","volume":"38","author":"E Schuler","year":"2014","unstructured":"Schuler\u00a0E, Schroeder\u00a0M, Neukirchen\u00a0J, et\u00a0al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413\u20139.","journal-title":"Leuk Res"},{"issue":"21","key":"1080_CR23","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/bloodadvances.2021004755","volume":"5","author":"N Radakovich","year":"2021","unstructured":"Radakovich\u00a0N, Meggendorfer\u00a0M, Malcovati\u00a0L, et\u00a0al. A\u00a0geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021;5(21):4361\u20139.","journal-title":"Blood Adv"},{"issue":"12","key":"1080_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","volume":"133","author":"C Cargo","year":"2019","unstructured":"Cargo\u00a0C, Cullen\u00a0M, Taylor\u00a0J, et\u00a0al. The use of targeted sequencing and flow cytometry to identify patients with a\u00a0clinically significant monocytosis. Blood. 2019;133(12):1325\u201334.","journal-title":"Blood"},{"issue":"1","key":"1080_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40537-021-00553-4","volume":"9","author":"K Batko","year":"2022","unstructured":"Batko\u00a0K, \u015al\u0119zak\u00a0A. The use of big data analytics in healthcare. J\u00a0Big Data. 2022;9(1):3.","journal-title":"J Big Data"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-025-01080-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:05:40Z","timestamp":1757171140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-025-01080-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":25,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s10354-025-01080-0","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Qian and K.\u00a0Geissler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}